Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMP9064 Monotherapy and in Combination with Senaparib in Advanced Solid Tumors
NCT05269316Phase 2Recruiting
- Sponsor
- IMPACT Therapeutics
- Start
- Feb 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of IMP9064 in solid tumor (advanced stage), sponsored by IMPACT Therapeutics. Started Feb 2022; status: recruiting.
02
Drugs
IMP9064
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05269316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05269316.